EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) is 21.71% higher on its value in year-to-date trading and has touched a low of $3.91 and a high of $13.98 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The EYPT stock was last observed hovering at around $10.54 in the last trading session, with the day’s gains setting it 813.24%.
Currently trading at $823.78K, the stock is 19.44% and 44.07% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.01 million and changing 1010284% at the moment leaves the stock 32.90% off its SMA200. EYPT registered 39.19% gain for a year compared to 6-month loss of 46.06%. The firm has a 50-day simple moving average (SMA 50) of $7.1982 and a 200-day simple moving average (SMA200) of $7.8029.
The stock witnessed a 73.99% gain in the last 1 month and extending the period to 3 months gives it a 71.12%, and is 16.26% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.54% over the week and 9.19% over the month.
EyePoint Pharmaceuticals Inc (EYPT) has around 165 employees, a market worth around $713.58M and $56.04M in sales. Profit margin for the company is -261.91%. Distance from 52-week low is 165.22% and -25.85% from its 52-week high. The company has generated returns on investments over the last 12 months (-45.77%).
with sales reaching $6.82M over the same period.The EPS is expected to shrink by -31.19% this year, but quarterly earnings will post -8.18% year-over-year. Quarterly sales are estimated to shrink -28.00% in year-over-year returns.
216.0 institutions hold shares in EyePoint Pharmaceuticals Inc (EYPT), with institutional investors hold 113.30% of the company’s shares. The shares outstanding are 68.81M, and float is at 59.81M with Short Float at 11.27%. Institutions hold 109.29% of the Float.
The top institutional shareholder in the company is CORMORANT ASSET MANAGEMENT, LP with over 8.32 million shares valued at $72.43 million. The investor’s holdings represent 15.6467 of the EYPT Shares outstanding. As of 2024-06-30, the second largest holder is SUVRETTA CAPITAL MANAGEMENT, LLC with 5.18 million shares valued at $45.03 million to account for 9.7279 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 3.76 million shares representing 7.076 and valued at over $32.75 million, while FRANKLIN RESOURCES INC holds 6.8595 of the shares totaling 3.65 million with a market value of $31.75 million.
EyePoint Pharmaceuticals Inc (EYPT) Insider Activity
The most recent transaction is an insider purchase by Zaderej Karen L., the company’s Director. SEC filings show that Zaderej Karen L. bought 5,000 shares of the company’s common stock on May 19 ’25 at a price of $5.99 per share for a total of $29950.0. Following the purchase, the insider now owns 36500.0 shares.
EyePoint Pharmaceuticals Inc disclosed in a document filed with the SEC on May 16 ’25 that Zaderej Karen L. (Director) bought a total of 5,000 shares of the company’s common stock. The trade occurred on May 16 ’25 and was made at $5.81 per share for $29050.0. Following the transaction, the insider now directly holds 31500.0 shares of the EYPT stock.
Still, SEC filings show that on May 15 ’25, Zaderej Karen L. (Director) acquired 5,000 shares at an average price of $5.47 for $27350.0. The insider now directly holds 26,500 shares of EyePoint Pharmaceuticals Inc (EYPT).
